Premium
pH‐Responsive Theranostic Polymer‐Caged Nanobins: Enhanced Cytotoxicity and T 1 MRI Contrast by Her2 Targeting
Author(s) -
Hong Bong Jin,
Swindell Elden P.,
MacRenaris Keith W.,
Hankins Patrick L.,
Chipre Anthony J.,
Mastarone Daniel J.,
Ahn Richard W.,
Meade Thomas J.,
O'Halloran Thomas V.,
Nguyen SonBinh T.
Publication year - 2013
Publication title -
particle and particle systems characterization
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 56
eISSN - 1521-4117
pISSN - 0934-0866
DOI - 10.1002/ppsc.201300158
Subject(s) - contrast (vision) , doxorubicin , dota , polymer , nanotechnology , magnetic resonance imaging , in vitro , mri contrast agent , chemistry , materials science , computer science , cancer research , nuclear magnetic resonance , medicine , physics , radiology , biochemistry , artificial intelligence , chelation , chemotherapy , nanoparticle , organic chemistry
A polymer‐caged nanobin (PCN) theranostic platform with a doxorubicin (DXR)‐loaded liposomal core and an acid‐sensitive polymer shell that is functionalized with herceptin and Gd III ‐based magnetic resonance imaging (MRI) contrast agents is reported. In vitro testing reveals an 120‐fold improvement in cellular Gd III uptake in comparison with clinically approved DOTA‐Gd III , leading to significant T 1 MRI contrast enhancement.